Using an integrated approach to study treatment resistance in clinical and murine pre‐clinical models of prostate cancer, we show that loss of tumour suppressor SPRY2, a negative regulator of receptor tyrosine kinase signalling, leads to CRPC. This evidence concerns the gene SPRY2 and prostate cancer.